AstraZeneca

AstraZeneca to Establish Global Drug Research Center in Beijing

Britain’s AstraZeneca wants to invest $2.5 billion in Beijing, China to establish its sixth global strategic R&D center.

AstraZeneca to Buy Vaccine Company Icosavax for $1.1 Billion

AstraZeneca has entered into an agreement to acquire Icosavax, a US biopharmaceutical company based in Seattle in a deal worth up to $1.1 billion. The company focuses on the development of differentiated vaccines with high potential using an innovative virus-like protein (VLP) particle platform.

AstraZeneca Granted Global Starmap AI License for Nanoform

Nanoform, a nanoparticle medical technology company, has awarded AstraZeneca a global online STARMAP license. STARMAP is an AI-based digital rendition of CESS technology, facilitating in-silico experiments for selecting molecules to be nanoformed. This license enables AstraZeneca to screen molecules during the entire drug development process.

AstraZeneca Gives Up on Targacept Antidepressant

Here To Stay